Fierce Biotech, "Finch Therapeutics, Takeda ink new microbiome GI collab"

"Microbiome biotech Finch Therapeutics has signed a pact with perennial U.S. life sciences dealmaker Takeda to jointly work on FIN-524, a microbial cocktail for inflammatory bowel disease (IBD).

Somerville, Massachusetts-based Finch Therapeutics is working on FIN-524, a live biotherapeutic in a preclinical stage that is composed of cultured bacterial strains which, the biotech says, have been linked to “favorable clinical outcomes” in studies of microbiota transplantations in IBD.

Finch will now team up with Takeda and tap into its experience in developing and selling gastrointestinal disease meds (one of its core areas), while the Osaka-based pharma gets to help advance a new class of microbial therapy."

Read the full article here